# Johnson & Johnson (jnj)

Generated: `2026-02-05T09:49:26Z`

- Assets: **45**
- Assets with linked trials: **19**
- Trials: **267**

## Top assets

| Asset | Highest stage | Linked trials | Example indications |
|---|---:|---:|---|
| Azacitidine | Registration | 4 | Cancer (ATLAS) intravesical delivery system) Invasive Bladder Cancer BCG; Cancer (ATLAS) intravesical delivery system) Invasive Bladder Cancer BCG (ORIGAMI-2) Multiple Myeloma CD38 exposed with DR (MajesTEC-7) |
| ypertension75mg | Registration | 0 | pipeline is based on the current status of these this information. *AC Immune ACI-35.030. of rilpivirine and cabotegravir: ViiV Healthcare; Tau Immunotherapy: AC Immune SA; Biotech; AKEEGA: TESARO, an oncology- iPSC-derived chimeric antigen receptor |
| PROTOSTAR | Registration | 0 | Arthritis Hemolytic Anemia (ENERGY) Alloimmune Thrombocytopenia |
| TALVEY + TECVAYLI | Phase 3 | 41 | Relapsed Refractory; Relapsed Refractory (MonumenTAL-6) |
| ERLEADA | Phase 3 | 27 | ASCT Localized Prostate |
| RYBREVANT | Phase 3 | 21 | Frontline Non Small; Colorectal Cancer |
| TREMFYA | Phase 3 | 8 | Ulcerative Colitis; Pediatric Ulcerative |
| INLEXZO | Phase 3 | 6 | High Risk High Risk Non Muscle Experienced (SunRISe-5) RYBREVANT (amivantamab) Colorectal Cancer TALVEY + TECVAYLI Relapsed Refractory (MonumenTAL-6) TALVEY (talquetamab) TIE NDMM in combination |
| nipocalimab | Phase 3 | 5 | Hemolytic Disease; Warm Autoimmune |
| bleximenib | Phase 3 | 5 | Relapsed Refractory 1) |
| SPRAVATO | Phase 3 | 3 | Major Depressive Disorder Pediatrics |
| icotrokinra | Phase 3 | 2 | Psoriatic Arthritis; Crohn's Disease (ICONIC-CD) |
| JNJ-7446 | Phase 3 | 2 | Lung Cancer |
| SIRTURO | Phase 3 | 0 | L e p r o s y under review by regulatory bodies. Inclusion in the & Johnson assumes no obligation to update Long acting HIV injectible treatment regimen; L e p r o s y under review by regulatory bodies. |
| PulmonaryArterialH | Phase 3 | 0 | SIRTUROLeprosyunderreviewbyregulatorybodies. |
| JNJ-8543 | Phase 3 | 0 | Hematological Malignancies |
| JNJ-4804 Co-antibody | Phase 3 | 0 | Psoriatic Arthritis; Crohn's Disease |
| JNJ-4681 | Phase 3 | 0 | Hematological Malignancies |
| JNJ-3413 | Phase 3 | 0 | Lymphoma |
| JNJ-2175 | Phase 3 | 0 | Solid Tumors |
| JNJ-1887 sCD59 | Phase 3 | 0 | Geographic Atrophy; Geographic Atrophy SPRAVATO (esketamine) Major Depressive Disorder Pediatrics |
| INLEXZO (gemcitabine | Phase 3 | 0 | Non Muscle Invasive; High Risk High Risk Non Muscle |
| Bleximenib | Phase 3 | 0 | Newly Diagnosed AML, with Venetoclax and |
| Gravis | Phase 2 | 43 | Indications for Major Depressive Disorder |
| amivantamab | Phase 2 | 27 | Cancer (ORIGAMI-5) |